|
For over two decades, India’s pharmaceutical industry has anchored both global healthcare and national industrial growth. With unmatched capacity for affordable, high-quality drug production, India today contributes an estimated 8 per cent to 10 per cent of global formulations supply and over 20 per cent of APIs by volume across 200+ countries. Notably, it supplies nearly 40 per cent of the generic medicines consumed in the United States and 25 per cent of those used in the United Kingdom, according to IBEF.
India’s scale advantage is equally visible in hard-coded trade performance. Pharmaceutical exports reached US$ 29 billion in FY 2024–25, up from US$ 16 billion in FY 2016–17, reflecting a steady compounded growth rate of nearly eight per cent. Even amid global economic headwinds, India’s exports have held firm. Between April and August 2025, India exported US$ 12.2 billion worth of pharmaceuticals, up 5.4 per cent year-on-year compared to US$ 11.6 billion in the same period of FY 2024–25.
This global reach has earned it the title of “pharmacy of the world”, a recognition built on technical rigor, compliance discipline, and manufacturing scale.
Yet this success story is not without its unique characteristics. The United States remains India’s single-largest export destination, accounting for roughly US$ 10.2 billion, or more than 30 per cent of total exports, followed by the United Kingdom (US$ 868 million) and Brazil (US$ 746 million) trailing far behind. This concentration reveals both strength and vulnerability: while the U.S. market provides scale and credibility, overdependence on one geography heightens exposure to policy risk.
Redrawing the trade map: The tariff wake-up call
While India’s export footprint continues to expand, the global rules of pharmaceutical trade are shifting. Nowhere is this more evident than in the United States, where policy rhetoric has again turned toward self-reliance in healthcare manufacturing.
In mid-2025, the proposed Trump tariff plan reintroduced trade uncertainty to the sector. Announced with a tentative implementation date of October 1, 2025, the plan proposed 100 per cent import duties on branded and patented pharmaceuticals unless the manufacturer maintained an active U.S. production facility. Though generics and APIs, the backbone of India’s exports, were largely exempt, and ambiguity around terms like “branded,” “specialty,” and “patented” remained unclarified.
While the plan was ultimately shelved amid political and legal scrutiny, it created ripples of concern. It served as a clear reminder that India’s trade security cannot rely solely on policy goodwill or market continuity. Structural competitiveness, underpinned by backward integration, diversified markets, and technology-led transparency, will define the next decade of leadership.
Across the Atlantic, too, the European Union’s revised GMP and API traceability regulations, set to take effect in 2026, are adding layers of compliance related to ingredient provenance, documentation transparency, and environmental impact. These shifts, while necessary for global safety standards, are pushing exporters to modernize systems and processes.
Adding to this complexity are freight disruptions, dollar volatility, and shifting definitions of “essential supply security” in global procurement strategies. The pandemic triggered a wave of friend-shoring and China-plus-one initiatives. While India benefitted from this pivot, these strategies now carry a new expectation: that suppliers demonstrate reliability, credibility, and partnership, not just capacity.
As global trade enters a more volatile era, marked by rising protectionism, currency fluctuations, and evolving regulatory frameworks, India’s pharmaceutical sector faces a defining question: can it fortify its global position before volatility erodes its hard-won advantage?
Frost & Sullivan’s outlook for India’s pharma sector is grounded in optimism and realism. Strategic reinvention will allow India to defend its export advantages, pivot nimbly in times of uncertainty, and capture greater value across the global pharmaceutical value chain. After all, from scaling Covid-19 vaccine production in record time to stabilizing global generic supply chains during pandemic-era bottlenecks, India has repeatedly demonstrated the ability to convert crisis into capability.
A strategic pivot at home
Indian pharmaceutical companies are not waiting for certainty; they are creating it. The leading players are investing in backward integration, expanding manufacturing presence in the US and Europe, and adopting digital traceability systems aligned with global compliance norms.
Several large firms have established or announced fill-finish and packaging units overseas to reduce logistics risk and accelerate regulatory approvals. Others have deepened their control over key intermediates to reduce dependence on Chinese imports, which still account for an estimated 60 per cent to 70 per cent of India’s API needs for select molecules.
Domestic policy support is also evolving in tandem. The Production-Linked Incentive (PLI) Scheme for APIs and Key Starting Materials, the creation of dedicated bulk drug parks, and the establishment of Pharma City initiatives are strengthening India’s base of manufacturing independence. Regulatory modernization under CDSCO, combined with the National GMP upgradation drive, signals a sector ready for the next level of global integration.
Pharma Vision 2047: Harboring new ambitions
India’s centenary goals are encapsulated in Pharma Vision 2047, a blueprint to position the country among the top five global innovation hubs while expanding the industry to US$ 120–130 billion in value. The vision is bold, but it is also pragmatic. It recognizes that India’s future competitiveness will depend less on being the lowest-cost producer and more on being a high-trust, high-capability innovation and trade partner.
At Frost & Sullivan, we see five critical levers that can
help the sector safeguard against short-term shocks while actualizing its long-term trade ambitions:
Expanding and diversifying export markets
India’s export map must broaden beyond its traditional anchors. Africa, Latin America, and Southeast Asia are emerging as high-growth regions, driven by rising healthcare access and maturing regulatory systems. India’s annual trade with Brazil, Nigeria, and South Africa now exceeds USD 500 million each, reflecting growing South–South collaboration. Expanding these ties will reduce vulnerability to western market cycles while deepening India’s footprint in high-demand therapeutic areas such as anti-infectives, chronic care, and oncology.
Technology-enabled compliance and visibility
As global regulators move toward real-time data transparency, India must lead rather than follow. Digital batch traceability, blockchain-based serialization, and AI-driven quality analytics can elevate India’s status from low-cost supplier to trusted partner, capable of proactive risk management and rapid adaptation as regulatory frameworks evolve. Early adoption of digital compliance infrastructure will help Indian manufacturers align with both the US FDA and EU regulatory shifts, minimizing trade friction and enhancing compliance.
Industry 4.0 and smart manufacturing
Digital transformation is becoming the baseline for competitiveness. Embedding AI, IoT, and predictive analytics into manufacturing can help Indian firms achieve consistency and efficiency comparable to global innovators. Smart manufacturing hubs, integrating data-driven operations and continuous production, could emerge as export-oriented clusters for complex molecules and specialty drugs, strengthening India’s quality assurance and supply reliability. With more than 650 US-FDA-compliant plants, the largest number outside the US, India should lead in not just volume but future-ready pharmaceutical manufacturing.
Backward integration and supply chain strengthening
Resilience in pharmaceutical exports fundamentally relies on control over the entire value chain. Backward integration, internalizing production of APIs, intermediates, and key starting materials, anchors cost stability and quality assurance. Currently, 60 per cent–70 per cent of APIs for select molecules are still imported, predominantly from China. Indian firms are investing in domestic facilities for key APIs and intermediates, reducing import dependence and strengthening negotiating leverage.
Backward integration not only provides cost control and quality assurance but also ability to control the entire value chain, from raw materials to finished formulations, which will anchor India’s self-reliance while allowing it to project long-term stability to global buyers.
R&D and innovation for value creation
The Indian pharmaceutical sector stands at a crossroads: while volume leadership is secure, value leadership demands higher and more targeted R&D investment. India currently spends six per cent to eight per cent of pharma revenue on R&D, while global leaders invest up to 20 per cent. Bridging this gap is essential for the transition to biosimilars, complex generics, and novel drug delivery systems. Public-private partnerships, academic collaborations, and policy incentives are increasingly supporting this step change.
Unlike many manufacturing sectors, India’s pharmaceutical trade is almost evenly split between domestic and export markets, a rare symmetry that gives it both scale and stability. The domestic market acts as a test bed for cost-sensitive innovation, while exports provide the global validation and capital flows required to sustain R&D investment. This dual structure will be critical to realizing the 2047 ambition.
Empowering startup ecosystem
A dynamic pharma-tech startup ecosystem could become India’s next growth engine. Startups specializing in AI-based molecule discovery, clinical trial digitization, and real-world evidence analytics can infuse agility and innovation scalability into a legacy-heavy industry. As Frost & Sullivan emphasizes, enabling startups through venture support and innovation clusters can accelerate India’s evolution from process excellence to innovation excellence, allowing the industry to innovate faster, fail faster, and reinvent faster.
A symbiotic global future
Despite periodic trade shocks, the India–U.S. pharmaceutical corridor remains fundamentally symbiotic. Nearly one in three pills consumed in the U.S. originates from India, making Indian firms integral to American healthcare affordability. In return, India gains access to the world’s most advanced regulatory ecosystem, fostering continuous improvement.
Maintaining this interdependence requires not just cost competitiveness but operational transparency, digital integration, and continuous innovation. A similar story unfolds in Europe, where Indian generics sustain affordability and supply continuity.
India’s trade strategy should lie not in isolation, but in integration, as a credible, trusted, and strategically aligned node in the global pharmaceutical network.
Futureproofing India’s pharma leadership
India’s pharmaceutical story is entering its next act. The first revolution was about scale and affordability; the next will be about adaptability, credibility, and innovation-driven trust.
If Indian pharmaceutical firms can leverage their domestic market as an innovation lab, broaden their export footprint, embed digital transformation, invest deeply in R&D, and empower a vibrant startup ecosystem, they will not merely weather global volatility; they will shape the future of global pharmaceutical supply.
In a world where policy cycles are short and disruptions are frequent, India’s trade resilience will be defined not by static advantages but by continuous foresight, investment, and global partnership. From this foundation, Pharma Vision 2047 is well within reach.
(The author is Associate Director, Healthcare &
Life Sciences Growth Advisory, Frost & Sullivan)
|